Altogether, these data support a role for tumor-infiltrating CD30+OX40+, but not CD30−OX40+ or CD30+OX40−, Foxp3+ Tregs in predicting OS of CRC patients. This evidence concerns the gene TNFRSF4 and colorectal carcinoma.